Vercruysse, Frank

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes

Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., et al. (2015) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 233

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

for the OBES-002 Study Group, Wilding, J., Gaal, L. V., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004) · International Journal of Obesity

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 224

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( CANVAS‐R ): A randomized, placebo‐controlled trial

Neal, B., Perkovic, V., Matthews, D. R., Mahaffey, K. W., Fulcher, G., Meininger, G., Erondu, N., Desai, M., Shaw, W., Vercruysse, F., et al. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 174

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

Li, J., Woodward, M., Perkovic, V., Figtree, G. A., Heerspink, H. J. L., Mahaffey, K. W., de Zeeuw, D., Vercruysse, F., Shaw, W., Matthews, D. R., et al. (2020) · JACC: Heart Failure

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 144

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial

Hollander, P., Bays, H. E., Rosenstock, J., Frustaci, M. E., Fung, A., Vercruysse, F., & Erondu, N. (2017) · Diabetes Care

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 106

Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes

Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Mathieu, C., Woo, V., Wysham, C., Capuano, G., Desai, M., et al. (2016) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 91

Effect of a dietary-induced weight loss on liver enzymes in obese subjects

Gasteyger, C., Larsen, T. M., Vercruysse, F., & Astrup, A. (2008) · The American Journal of Clinical Nutrition

Liver Disease Diagnosis and TreatmentBariatric Surgery and Outcomes

Cited by 75

Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial

Eliasson, B., Gudbjörnsdottir, S., Cederholm, J., Liang, Y., Vercruysse, F., & Smith, U. (2007) · International Journal of Obesity

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 57

Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial

Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Weiss, R., Rosenstock, J., Capuano, G., Desai, M., Shaw, W., et al. (2015) · Diabetes Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 44